Centre Paul Strauss

Running trials

• Recruiting

  Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse

  NCT07871864· Phase 3· Source

• Not yet recruiting

  Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers

  NCT07437287· Phase 2/3· Source

• Not yet recruiting

  Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01)

  NCT07337447· Phase 2· Source

• Recruiting

  Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study

  NCT05653635· Phase 2· Source

• Recruiting

  Irradiation in Paediatrics: Neurocognition, Neuroimaging and Evaluation of Memory and Attention

  NCT06599879· Source

• Recruiting

  Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI.

  NCT07195344· Phase 4· Source

• Recruiting

  Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Durvalumab

  NCT06796114· Source

• Recruiting

  Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated Glioblastoma

  NCT05653622· Phase 2· Source

• Recruiting

  Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib

  NCT06620835· Phase 2· Source

• Recruiting

  Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer

  NCT06600802· Source

• Active, not recruiting

  Treatment of microstellite stable metastatic colorectal cancer presenting high immune infiltrate with chemotherapy (XELOX or FOLFOX Bevacizumab) and immunotherapy ( Pembrolizumab)

  NCT04262687· Phase 2· Source

• Recruiting

  Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers

  NCT06425133· Phase 2· Source

• Recruiting

  Superiority Trial Evaluating Digitalized Information Media for Patients With Advanced Sarcomas Receiving Systemic Treatment.

  NCT06211257· Source

• Recruiting

  A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer

  NCT05639413· Source

• Recruiting

  Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC

  NCT05122806· Source

• Recruiting

  EULAT Eradicate GBC

  NCT06192719· Source

• Recruiting

  High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

  NCT04221035· Phase 3· Source

• Recruiting

  PD-(L)1 iNhibitors with concurrent IRadiation at VAried tumour sites in advanced Non-small cell lung cAncer

  2024-512173-27-00· Phase 3· Source

• Active, not recruiting

  Stereotactic Body Radiation Therapy (SBRT) Efficiency and Toxicity in Liver Cancer

  NCT03408665· Source

• Active, not recruiting

  PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer

  NCT03774732· Phase 3· Source

• Recruiting

  Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)

  NCT03848052· Source

• Active, not recruiting

  Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

  NCT02947685· Phase 3· Source

• Active, not recruiting

  Tracking Triple-negative Breast Cancer Evolution Through Therapy

  NCT03077776· Source

• Recruiting

  Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008

  NCT03275311· Source

• Active, not recruiting

  Trial of Superiority of Stereotactic Body Radiation Therapy in Patients With Breast Cancer

  NCT02089100· Phase 3· Source

• Active, not recruiting

  Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma

  NCT01924819· Phase 2/3· Source

• Active, not recruiting

  Radiation Therapy in Treating Patients Receiving Hormone Therapy for Prostate Cancer (GETUG-AFU 18)

  NCT00967863· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer4 recruiting
• Childhood cancers3 recruiting
• Liver and biliary tract cancer3 recruiting
• Colorectal cancer2 recruiting
• Glioblastoma2 recruiting
• Metastatic breast cancer2 recruiting
• Sarcoma2 recruiting
• Neuroblastoma1 recruiting
• Neuroendocrine tumours1 recruiting
• Prostate cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Impact on Quality of Life and Health of the CONTINUUM+ CONNECT Remote Monitoring Solution

  NCT06379880· Source

• Completed

  Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)

  NCT06525675· Source

• Terminated

  Futibatinib in Patients With Specific FGFR Aberrations

  NCT04189445· Phase 2· Source

• Completed

  A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

  NCT04042558· Phase 2· Source

• Completed

  Trial evaluating the tolerance and safety of durvalumab - radiotherapy combination for treatment of cancers of the head and neck

  2024-513977-31-00· Phase 2· Source

• Completed

  FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel

  NCT03723967· Phase 2· Source

• Completed

  Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck

  NCT03818061· Phase 2· Source

• Completed

  FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation

  NCT03584711· Phase 2· Source

• Terminated

  A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

  NCT03248492· Phase 2· Source

• Terminated

  Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels

  NCT03117972· Phase 2· Source

• Completed

  PHASE III RANDOMISED TRIAL to EVALUATE FOLFOX with or WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY for LOCALLY ADVANCED or METASTATIC OESOPHAGO-GASTRIC CARCINOMA

  NCT03006432· Phase 3· Source

• Completed

  ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab

  NCT02891824· Phase 3· Source

• Completed

  Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

  NCT02003924· Phase 3· Source

• Completed

  Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation

  NCT00673335· Phase 3· Source